New Zealanders usually notice Pharmac when a medicine is not funded, when a family starts a public campaign, or when a new treatment overseas appears out of reach at home. The agency’s work is technical, but its consequences are intimate. A decision can decide whether a patient gets more time, fewer symptoms, less financial stress, or a treatment that feels like the difference between hope and being left behind.
The Government’s latest expectations for Pharmac continue a theme that has been building for years: move faster, communicate better, be clearer about records and keep improving the way funding choices are made. That sounds straightforward until one remembers what Pharmac actually does. It is not simply approving medicines. It is deciding how to spend a limited public budget across many possible treatments, conditions and patient groups. Every “yes” has an opportunity cost; every “not yet” lands on a real person.
Why speed matters
Time is not neutral in medicine. A funding application that sits unresolved can mean patients deteriorate, clinicians improvise, families fundraise, and public trust erodes. When other comparable countries fund a medicine earlier, New Zealand patients understandably ask why they are waiting. The question becomes sharper for cancer, rare disease and chronic conditions where treatment windows can be narrow.
Speed also matters because pharmaceutical innovation does not pause for public administration. New therapies, combinations, devices and diagnostics keep arriving. If assessment systems move too slowly, the backlog becomes its own policy. The agency then spends more energy explaining the queue than making timely choices.
Why speed alone is dangerous
But faster is not automatically fairer. A medicine can be promising, expensive and emotionally compelling without being the best use of a limited budget. Some treatments have strong trial evidence; others arrive with uncertainty about long-term benefit, subgroup effects or real-world value. If political pressure pushes the loudest cases to the front, quieter conditions and less organised patient groups may lose out.
That is why transparency matters as much as speed. People may disagree with a decision, but they should be able to understand the pathway: what evidence was considered, what advice was received, what uncertainties remained, and why a treatment was funded, declined, deferred or ranked where it was. Decision records are not bureaucratic decoration. They are how a rationing system earns legitimacy.
The public misunderstands rationing because politicians avoid the word
New Zealand’s medicine funding debate is often conducted as if every delay is a failure of compassion. Sometimes it is. But the harder truth is that public health systems ration. They ration through budgets, workforce, operating theatres, specialist appointments, screening programmes and drug funding. Pharmac’s rationing is unusually visible because a medicine either appears on the schedule or it does not.
A mature debate would admit the trade-off openly. New Zealand can choose to fund more medicines by increasing the budget, changing thresholds, accepting more uncertainty, negotiating differently with suppliers, or reducing spending elsewhere. Each choice has consequences. Pretending there is a technical fix that removes scarcity only sets the agency up to absorb public anger that belongs partly to the political system.
Patients need clarity before crisis
For patients and clinicians, the most frustrating part is often not only the final answer but the fog around the process. Where is an application? What does “under assessment” mean in practical time? What additional evidence is needed? How are patient voices considered? When will a medicine be reconsidered? Better public records can reduce that fog.
Good transparency should not mean dumping dense documents online. It should mean plain-language summaries, clear timelines, readable reasons, accessible consultation material and consistent updates. It should also mean being honest when the answer is painful: the evidence is uncertain, the price is too high, the budget cannot stretch, or another medicine offers better value.
The supplier side of the story
Drug companies are not passive observers in this system. Prices, data quality, willingness to negotiate, managed access proposals and timing all affect outcomes. Public anger often lands on Pharmac because it is the visible gatekeeper, but suppliers also make commercial decisions about how hard to push price, what evidence to provide and whether New Zealand is treated as a priority market.
That is another reason detailed records matter. If the public can see more of the decision logic without compromising legitimate commercial confidentiality, blame can be placed more accurately. Sometimes the problem is process. Sometimes it is evidence. Sometimes it is budget. Sometimes it is price. Often it is all of them together.
The real test for 2026
The 2026 expectations should be judged not by whether every campaign gets the answer it wants, but by whether Pharmac becomes easier to understand, quicker where delay is avoidable, and clearer where delay is the result of real trade-offs. A faster opaque system would not solve the trust problem. A transparent but sluggish system would not solve the patient problem. New Zealand needs both: timely decisions and reasons people can inspect.
The deeper issue is democratic. Medicine funding decisions are too important to be treated as either pure technocracy or pure politics. Pharmac must remain evidence-driven, but the public deserves to see how evidence, value, budget and human need are weighed. In a small country with a fixed budget, that openness is not a luxury. It is the price of asking people to accept hard decisions.
Sources: Ministerial expectations for Pharmac in 2026, Pharmac’s funding-process information and Pharmac consultations and decisions.
